PET/CT staging of Hodgkin lymphoma in no need of routine BMB

11/14/2012 | DoctorsLounge.com

Routine bone marrow biopsy did not have a significant effect on treatment management in patients with treatment-naive Hodgkin lymphoma staged with 18F-FDG-PET/CT, according to a study in the Journal of Clinical Oncology. "The added diagnostic value from routine BMB was minimal, and positive BMB findings implied upstaging in only five patients from stage III to stage IV disease of a total of 454 included patients," researchers said.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA